Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 6, 2012, Pages 737-745

  Zheng, S ^a   Tasnif, Y ^a   Hebert, M F ^a   Davis, C L ^a   Shitara, Y ^a   Calamia, J C ^a   Lin, Y S ^a   Shen, D D ^a   Thummel, K E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXYTACROLIMUS; 13 NORTACROLIMUS; 31 NORTACROLIMUS; CYTOCHROME P450 3A5; DRUG METABOLITE; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXCRETION; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; KIDNEY EPITHELIUM; NORMAL HUMAN; PRIORITY JOURNAL; STEADY STATE; URINARY EXCRETION;

ADULT; ALGORITHMS; AREA UNDER CURVE; BIOTRANSFORMATION; CYTOCHROME P-450 CYP3A; DNA; FEMALE; GENETIC VARIATION; GENOTYPE; HALF-LIFE; HETEROZYGOTE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; MODELS, GENETIC; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS;

EID: 84869501187     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.175     Document Type: Article

References (47)

1. Scott, L.J., McKeage, K., Keam, S.J. & Plosker, G.L. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 63, 1247-1297 (2003). (Pubitemid 36750952)
2. Ojo, A.O. et al. Chronic renal failure after transplantation of a nonrenal organ. N. Engl. J. Med. 349, 931-940 (2003). (Pubitemid 37064766)
3. Ekberg, H. et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 357, 2562-2575 (2007). (Pubitemid 350294223)
4. Metalidis, C., Lerut, E., Naesens, M. & Kuypers, D.R. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. Transplantation 91, 1098-1102 (2011).
5. Naesens, M., Kuypers, D.R. & Sarwal, M. Calcineurin inhibitor nephrotoxicity. Clin. J. Am. Soc. Nephrol. 4, 481-508 (2009).
6. Fukudo, M. et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet. Genomics 18, 413-423 (2008). (Pubitemid 351535942)
7. Kuypers, D.R., Naesens, M., de Jonge, H., Lerut, E., Verbeke, K. & Vanrenterghem, Y. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther. Drug Monit. 32, 394-404 (2010).
8. Kuypers, D.R., de Jonge, H., Naesens, M., Lerut, E., Verbeke, K. & Vanrenterghem, Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drugrelated nephrotoxicity in renal recipients. Clin. Pharmacol. Ther. 82, 711-725 (2007). (Pubitemid 350114816)
9. Min, S.I. et al. CYP3A5*1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. Transplantation 90, 1394-1400 (2010).
10. Sattler, M., Guengerich, F.P., Yun, C.H., Christians, U. & Sewing, K.F. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab. Dispos. 20, 753-761 (1992).
11. Lampen, A. et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab. Dispos. 23, 1315-1324 (1995). (Pubitemid 26007838)
12. Lin, Y.S. et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol. 62, 162-172 (2002). (Pubitemid 34680528)
13. Kuehl, P. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001). (Pubitemid 32268418)
14. Haehner, B.D. et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol. Pharmacol. 50, 52-59 (1996). (Pubitemid 26250074)
15. Givens, R.C. et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J. Appl. Physiol. 95, 1297-1300 (2003). (Pubitemid 37034028)
16. Dai, Y. et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab. Dispos. 34, 836-847 (2006).
17. Kamdem, L.K. et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin. Chem. 51, 1374-1381 (2005). (Pubitemid 41060869)
18. Bolbrinker, J. et al. CYP3A5 genotype-phenotype analysis in the human kidney reveals a strong site-specific expression of CYP3A5 in the proximal tubule in carriers of the CYP3A5*1 allele. Drug Metab. Dispos. 40, 639-641 (2012).
19. Hesselink, D.A. et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74, 245-254 (2003). (Pubitemid 37083100)
20. Haufroid, V. et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14, 147-154 (2004). (Pubitemid 38373108)
21. Thervet, E. et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76, 1233-1235 (2003). (Pubitemid 37339651)
22. Staatz, C.E. & Tett, S.E. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin. Pharmacokinet. 43, 623-653 (2004). (Pubitemid 38981845)
23. Minematsu, T. et al. Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients. Transplant. Proc. 36, 1506-1511 (2004). (Pubitemid 38903017)
24. Sirianni, G.L. & Pang, K.S. Inhibition of esterolysis of enalapril by paraoxon increases the urinary clearance in isolated perfused rat kidney. Drug Metab. Dispos. 27, 931-936 (1999). (Pubitemid 29347594)
25. Staatz, C.E., Goodman, L.K. & Tett, S.E. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin. Pharmacokinet. 49, 207-221 (2010).
26. de Denus, S. et al. Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors. J. Heart Lung Transplant. 30, 326-331 (2011).
27. Klauke, B. et al. No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation. J. Heart Lung Transplant. 27, 741-745 (2008).
28. Glowacki, F. et al. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation. Nephrol. Dial. Transplant. 26, 3046-3050 (2011).
29. Sigal, N.H. et al. Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? J. Exp. Med. 173, 619-628 (1991).
30. Kung, L., Batiuk, T.D., Palomo-Pinon, S., Noujaim, J., Helms, L.M. & Halloran, P.F. Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine. Am. J. Transplant. 1, 325-333 (2001). (Pubitemid 33681696)
31. Iwasaki, K. et al. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab. Dispos. 23, 28-34 (1995).
32. Hebert, M.F. et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin. Pharmacol. Ther. 84, 248-253 (2008).
33. Asano, T. et al. ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics 13, 675-682 (2003). (Pubitemid 38316511)
34. Chen, Y.L., Hirabayashi, H., Akhtar, S., Pelzer, M. & Kobayashi, M. Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatographytandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 830, 330-341 (2006). (Pubitemid 43075470)
35. Zheng, S.et al. Pharmacokinetics of tacrolimus during pregnancy. Ther. Drug Monit.(in press).
36. Barrett, P.H. et al. SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. Metab. Clin. Exp. 47, 484-492 (1998). (Pubitemid 28180958)
37. Lohr, J.W., Willsky, G.R. & Acara, M.A. Renal drug metabolism. Pharmacol. Rev. 50, 107-141 (1998). (Pubitemid 28158844)
38. Cockcroft, D.W. & Gault, M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41 (1976).
39. Levey, A.S. et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann. Intern. Med. 145, 247-254 (2006). (Pubitemid 46768608)
40. Klahr, S. & Morrissey, J. Obstructive nephropathy and renal fibrosis. Am. J. Physiol. Renal Physiol. 283, F861-F875 (2002). (Pubitemid 35192452)
41. Cheong, B., Muthupillai, R., Rubin, M.F. & Flamm, S.D. Normal values for renal length and volume as measured by magnetic resonance imaging. Clin. J. Am. Soc. Nephrol. 2, 38-45 (2007).
42. Myers, B.D., Deen, W.M. & Brenner, B.M. Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. Circ. Res. 37, 101-110 (1975).
43. Qin, X.L. et al. Study of the effect of Wuzhi tablet (Schisandra sphenanthera extract) on tacrolimus tissue distribution in rat by liquid chromatography tandem mass spectrometry method. Biomed. Chromatogr. 24, 399-405 (2010).
44. Wu, C.Y. & Benet, L.Z. Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. Drug Metab. Dispos. 31, 1292-1295 (2003). (Pubitemid 37310314)
45. Anastasio, P., Cirillo, M., Spitali, L., Frangiosa, A., Pollastro, R.M. & De Santo, N.G. Level of hydration and renal function in healthy humans. Kidney Int. 60, 748-756 (2001). (Pubitemid 32678919)
46. Ronis, M.J., Huang, J., Longo, V., Tindberg, N., Ingelman-Sundberg, M. & Badger, T.M. Expression and distribution of cytochrome P450 enzymes in male rat kidney: effects of ethanol, acetone and dietary conditions. Biochem. Pharmacol. 55, 123-129 (1998). (Pubitemid 28006178)
47. Ghosh, S.S. et al. Renal and hepatic family 3A cytochromes P450 (CYP3A) in spontaneously hypertensive rats. Biochem. Pharmacol. 50, 49-54 (1995).